GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Earnings per Share (Diluted)

BCTX (BriaCell Therapeutics) Earnings per Share (Diluted) : $-5.03 (TTM As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is BriaCell Therapeutics Earnings per Share (Diluted)?

BriaCell Therapeutics's Earnings per Share (Diluted) for the three months ended in Jan. 2025 was $-2.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was $-5.03.

BriaCell Therapeutics's EPS (Basic) for the three months ended in Jan. 2025 was $-2.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2025 was $-5.03.

BriaCell Therapeutics's EPS without NRI for the three months ended in Jan. 2025 was $-2.64. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2025 was $-17.55.

During the past 3 years, the average EPS without NRIGrowth Rate was -12.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 27.80% per year.

During the past 13 years, BriaCell Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 51.00% per year. The lowest was -130.90% per year. And the median was -4.35% per year.


BriaCell Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for BriaCell Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Earnings per Share (Diluted) Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -84.60 -45.90 -25.95 -19.50 -4.35

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.64 1.65 -1.05 -3.30 -2.33

Competitive Comparison of BriaCell Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, BriaCell Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's PE Ratio falls into.


;
;

BriaCell Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

BriaCell Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Jul. 2024 is calculated as

Diluted Earnings Per Share (A: Jul. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.791-0)/1.097
=-4.37

BriaCell Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Jan. 2025 is calculated as

Diluted Earnings Per Share (Q: Jan. 2025 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-6.291-0)/2.700
=-2.33

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


BriaCell Therapeutics  (NAS:BCTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BriaCell Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0